type of report	Current report
number	46/2013
company	PHARMENA

Summary of subscription of series D shares

The Management Board of PHARMENA S.A. informs that on 28thJune 2013, it adopted a resolution on allocation of series D shares with pre-emptive rights.

- 1) Date of starting and finishing of subscription: date of starting of subscription: 5th June 2013 date of finishing of subscription: 19th June 2013
- 2) Date of allocation of shares: 28th June 2013
- 3) Number of shares covered by the subscription: up to do 1,759,010 series D shares
- 4) Reduction rate within the additional subscriptions: 98.36%
- 5) Number of shares allocated under the carried out subscription: 1,759,010 series D shares
- 6) Issue price for which the shares were subscribed:
- 7.5 PLN per 1 share
- 7) Number of investors who subscribed for shares covered by the subscription in individual tranches:
- 67 investors within basic subscriptions
- 9 investors within additional subscriptions
- 8) Number of investors who were allocated the shares within the carried out subscription in individual tranches:
- 67 investors within basic subscriptions
- -7 investors within additional subscriptions
- 9) Names (business names) of underwriters who took up shares in the performance of underwriting agreements: no underwriters took part in subscription of series D shares.
- 10) Total cost of the issue of series D shares is ca. 389,300 PLN net, including:
- costs of preparing and carrying out the offering: ca. 192,535 PLN net,
- remuneration for underwriters: 0 PLN net,
- costs of preparing the issue prospectus, including the costs of counselling services: 138,300 PLN net,
- costs of promoting of the offering: 58,465 PLN net.

Pursuant to Art. 36 (2b) of accounting act, the costs of issue of shares incurred during the increase of share capital reduce the supplementary capital up to the amount of surplus value of issue over the nominal value of share ("agio"), whereas, the remaining part is calculated as financial costs.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 4 (1).

Representatives of the company:

- Konrad Palka President of the Board
- Marzena Wieczorkowska Vice President of the Board